Arlene O. Siefker-Radtke, MD, on Combination Therapy With Erdafitinib and Cetrelimab for Metastatic Urothelial Carcinoma

Posted: Wednesday, June 7, 2023

Arlene O. Siefker-Radtke, MD, of The University of Texas MD Anderson Cancer Center, discusses the results from the NORSE trial. In this study, combination therapy with the FGFR inhibitor erdafitinib and the PD-1 inhibitor cetrelimab appeared to be active and well tolerated in cisplatin-ineligible patients who had metastatic urothelial carcinoma and FGFR alterations.